A randomized trial of in-hospital initiation of an SGLT2 inhibitor in patients with heart failure missed its endpoint, but a ...

Over 3 years, SGLT2 inhibitors were safely associated with a nearly one third reduction in the risk for serious liver events.

In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening ...

The drug lowered inflammation, oxidative stress, and endothelial injury markers in women with INOCA and coronary ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

As the prevalence of both chronic kidney disease (CKD) and heart failure (HF) increases, therapies targeting shared pathways ...

NICE has removed a requirement in its guidance on chronic heart failure for GPs to seek specialist advice before prescribing ...

MADRID, Spain—The DAPA ACT HF – TIMI 68 trial has failed to show a significant improvement in outcomes when starting dapagliflozin (Farxiga; AstraZeneca) during an acute heart failure (HF) ...

Jennie Barlow, Pharm.D., MBA, associate vice president, pharmacy industry relations for Scripius, discusses cost savings from ...